Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

被引：27
作者：
Galsky, Matthew D. [1 ]
Balar, Arjun, V [2 ]
Black, Peter C. [3 ]
Campbell, Matthew T. [4 ]
Dykstra, Gail S. [5 ,6 ]
Grivas, Petros [7 ,8 ]
Gupta, Shilpa [9 ]
Hoimes, Christoper J. [10 ]
Lopez, Lidia P. [11 ]
Meeks, Joshua J. [12 ,13 ]
Plimack, Elizabeth R. [14 ]
Rosenberg, Jonathan E. [15 ,16 ]
Shore, Neal [17 ]
Steinberg, Gary D. [18 ,19 ]
Kamat, Ashish M. [20 ]
机构：
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[2] NYU, Perlmutter Canc Ctr, Langone Med Ctr, New York, NY USA
[3] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX 77030 USA
[5] Bladder Canc Advocacy Network BCAN, Bethesda, MD USA
[6] Dykstra Res, Washington, DC USA
[7] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[8] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA
[9] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[10] Duke Univ, Dept Med, Duke Canc Inst, Durham, NC USA
[11] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA
[12] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[13] Jesse Brown VA Med Ctr, Chicago, IL USA
[14] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[15] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[16] Weill Cornell Med Coll, Dept Med, New York, NY USA
[17] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[18] NYU Langone Med Ctr, Dept Urol, New York, NY USA
[19] NYU Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA
[20] Univ Texas MD Anderson Canc Ctr, Dept Urol, Div Surg, Houston, TX 77030 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 07期
关键词：
antineoplastic protocols; guidelines as topic; immunotherapy; urinary bladder neoplasms; urologic neoplasms; BACILLUS-CALMETTE-GUERIN; INVASIVE BLADDER-CANCER; QUALITY-OF-LIFE; CISPLATIN-INELIGIBLE PATIENTS; T1 PAPILLARY CARCINOMA; HIGH-RISK TA; PHASE-III; ENFORTUMAB VEDOTIN; INTRAVESICAL BCG; DOUBLE-BLIND;
D O I：
10.1136/jitc-2021-002552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.
引用
收藏
页数：21
相关论文
共 154 条
  • [1] Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
    Alva, A.
    Csoszi, T.
    Ozguroglu, M.
    Matsubara, N.
    Geczi, L.
    Cheng, S. Y-S.
    Fradet, Y.
    Oudard, S.
    Vulsteke, C.
    Morales Barrera, R.
    Flechon, A.
    Gunduz, S.
    Loriot, Y.
    Rodriguez-Vida, A.
    Mamtani, R.
    Yu, E. Y.
    Nam, K.
    Imai, K.
    Moreno, B. H.
    Powles, T. B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1155 - S1155
  • [2] [Anonymous], STUDY PEMBROLIZUMAB
  • [3] Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.
    Apolo, Andrea B.
    Ellerton, John Allan
    Infante, Jeffrey R.
    Agrawal, Manish
    Gordon, Michael S.
    Aljumaily, Raid
    Britten, Carolyn D.
    Dirix, Luc
    Lee, Keun-Wook
    Taylor, Matthew H.
    Schoffski, Patrick
    Wang, Ding
    Ravaud, Alain
    Xiong, Junyuan
    Rosen, Galit
    Gulley, James L.
    Patel, Manish R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
    Arnaud-Coffin, Patrick
    Maillet, Denis
    Gan, Hui K.
    Stelmes, Jean-Jacques
    You, Benoit
    Dalle, Stephane
    Peron, Julien
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) : 639 - 648
  • [5] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
    Babjuk, Marko
    Burger, Maximilian
    Comperat, Eva M.
    Gontero, Paolo
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard
    Zigeuner, Richard
    Capoun, Otakar
    Cohen, Daniel
    Dominguez Escrig, Jose Luis
    Hernandez, Virginia
    Peyronnet, Benoit
    Seisen, Thomas
    Soukup, Viktor
    [J]. EUROPEAN UROLOGY, 2019, 76 (05) : 639 - 657
  • [6] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Hernandez, Virginia
    Kaasinen, Eero
    Palou, Joan
    Roupret, Morgan
    van Rhijn, Bas W. G.
    Shariat, Shahrokh F.
    Soukup, Viktor
    Sylvester, Richard J.
    Zigeuner, Richard
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 447 - 461
  • [7] First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
    Bajorin, Dean F.
    Witjes, Johannes Alfred
    Gschwend, Jurgen
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh
    Park, Se Hoon
    Ye Dingwei
    Agerbaek, Mads
    Collette, Sandra
    Unsal-Kacmaz, Keziban
    Zardavas, Dimitrios
    Koon, Henry B.
    Galsky, Matt D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Balar, 2019, ASCO GU 2019 RESULTS
  • [9] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
  • [10] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
12345678910